Concentra Group Holdings Parent, Inc.
Concentra Group Holdings Parent, Inc. (CON) Stock Competitors & Peer Comparison
See (CON) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Equipment & Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CON | $25.53 | -2.11% | 3.3B | 18.37 | $1.39 | +0.97% |
| SIRO | $109.97 | +0.00% | 22B | N/A | N/A | N/A |
| HIMS | $22.44 | +0.67% | 4.9B | -249.28 | -$0.09 | N/A |
| NVST | $23.05 | -0.43% | 3.7B | 56.20 | $0.41 | N/A |
| NAKA | $0.17 | +0.41% | 3.4B | -0.36 | -$0.47 | N/A |
| BBNX | $9.42 | +0.21% | 418.9M | -6.86 | -$1.37 | N/A |
| CV | $6.57 | +3.30% | 328.3M | -6.20 | -$1.06 | N/A |
| KDLY | $11.30 | +1.16% | 68.1M | -15.48 | -$0.73 | N/A |
| NEUE | $6.75 | +0.00% | 60.9M | -0.38 | -$17.65 | N/A |
| PARK | $18.79 | +1.60% | 36.5M | -104.39 | -$0.18 | N/A |
Stock Comparison
CON vs SIRO Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, CON is priced at $25.53, while SIRO trades at $109.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas SIRO's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, CON is more volatile compared to SIRO. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check SIRO's competition here
CON vs HIMS Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, HIMS has a market cap of 4.9B. Regarding current trading prices, CON is priced at $25.53, while HIMS trades at $22.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas HIMS's P/E ratio is -249.28. In terms of profitability, CON's ROE is +0.46%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, CON is less volatile compared to HIMS. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check HIMS's competition here
CON vs NVST Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, NVST has a market cap of 3.7B. Regarding current trading prices, CON is priced at $25.53, while NVST trades at $23.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas NVST's P/E ratio is 56.20. In terms of profitability, CON's ROE is +0.46%, compared to NVST's ROE of +0.02%. Regarding short-term risk, CON is more volatile compared to NVST. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check NVST's competition here
CON vs NAKA Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, NAKA has a market cap of 3.4B. Regarding current trading prices, CON is priced at $25.53, while NAKA trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas NAKA's P/E ratio is -0.36. In terms of profitability, CON's ROE is +0.46%, compared to NAKA's ROE of -0.85%. Regarding short-term risk, CON is less volatile compared to NAKA. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check NAKA's competition here
CON vs BBNX Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, BBNX has a market cap of 418.9M. Regarding current trading prices, CON is priced at $25.53, while BBNX trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas BBNX's P/E ratio is -6.86. In terms of profitability, CON's ROE is +0.46%, compared to BBNX's ROE of -0.23%. Regarding short-term risk, CON is less volatile compared to BBNX. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check BBNX's competition here
CON vs CV Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, CV has a market cap of 328.3M. Regarding current trading prices, CON is priced at $25.53, while CV trades at $6.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas CV's P/E ratio is -6.20. In terms of profitability, CON's ROE is +0.46%, compared to CV's ROE of +1.27%. Regarding short-term risk, CON is less volatile compared to CV. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check CV's competition here
CON vs KDLY Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, CON is priced at $25.53, while KDLY trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas KDLY's P/E ratio is -15.48. In terms of profitability, CON's ROE is +0.46%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, CON is less volatile compared to KDLY. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check KDLY's competition here
CON vs NEUE Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, CON is priced at $25.53, while NEUE trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas NEUE's P/E ratio is -0.38. In terms of profitability, CON's ROE is +0.46%, compared to NEUE's ROE of +0.09%. Regarding short-term risk, CON is more volatile compared to NEUE. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check NEUE's competition here
CON vs PARK Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, PARK has a market cap of 36.5M. Regarding current trading prices, CON is priced at $25.53, while PARK trades at $18.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas PARK's P/E ratio is -104.39. In terms of profitability, CON's ROE is +0.46%, compared to PARK's ROE of -0.24%. Regarding short-term risk, CON is less volatile compared to PARK. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check PARK's competition here
CON vs BRK Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, BRK has a market cap of 11.6M. Regarding current trading prices, CON is priced at $25.53, while BRK trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas BRK's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to BRK's ROE of N/A. Regarding short-term risk, CON is more volatile compared to BRK. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check BRK's competition here
CON vs PFSA Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, PFSA has a market cap of 225.2K. Regarding current trading prices, CON is priced at $25.53, while PFSA trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas PFSA's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to PFSA's ROE of +1.54%. Regarding short-term risk, CON is less volatile compared to PFSA. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check PFSA's competition here
CON vs SPNC Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, SPNC has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while SPNC trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas SPNC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, CON is more volatile compared to SPNC. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check SPNC's competition here
CON vs MZOR Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, MZOR has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while MZOR trades at $58.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas MZOR's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, CON is more volatile compared to MZOR. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check MZOR's competition here
CON vs PMC Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, PMC has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while PMC trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas PMC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to PMC's ROE of +0.04%. Regarding short-term risk, CON is more volatile compared to PMC. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check PMC's competition here
CON vs SCAI Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, SCAI has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while SCAI trades at $55.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas SCAI's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, CON is more volatile compared to SCAI. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check SCAI's competition here
CON vs STJ Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, STJ has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while STJ trades at $80.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas STJ's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to STJ's ROE of +0.21%. Regarding short-term risk, CON is more volatile compared to STJ. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check STJ's competition here
CON vs DSCI Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, DSCI has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while DSCI trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas DSCI's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, CON is more volatile compared to DSCI. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check DSCI's competition here
CON vs AMSG Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, AMSG has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while AMSG trades at $67.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas AMSG's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, CON is less volatile compared to AMSG. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check AMSG's competition here
CON vs SPAN Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, SPAN has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while SPAN trades at $29.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas SPAN's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, CON is less volatile compared to SPAN. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check SPAN's competition here
CON vs EXAC Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, EXAC has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while EXAC trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas EXAC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, CON is more volatile compared to EXAC. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check EXAC's competition here
CON vs ABAX Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, ABAX has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while ABAX trades at $83.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas ABAX's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, CON is more volatile compared to ABAX. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check ABAX's competition here
CON vs COTV Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, COTV has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while COTV trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas COTV's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to COTV's ROE of +0.14%. Regarding short-term risk, CON is more volatile compared to COTV. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check COTV's competition here
CON vs LDR Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, LDR has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while LDR trades at $67.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas LDR's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to LDR's ROE of +1.17%. Regarding short-term risk, CON is more volatile compared to LDR. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check LDR's competition here
CON vs LPNT Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, LPNT has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while LPNT trades at $64.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas LPNT's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, CON is more volatile compared to LPNT. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check LPNT's competition here
CON vs MEDC Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, MEDC has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while MEDC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas MEDC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to MEDC's ROE of N/A. Regarding short-term risk, CON is less volatile compared to MEDC. This indicates potentially lower risk in terms of short-term price fluctuations for CON.Check MEDC's competition here
CON vs EVHC Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, EVHC has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while EVHC trades at $45.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas EVHC's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, CON is more volatile compared to EVHC. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check EVHC's competition here
CON vs ABCO Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, ABCO has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while ABCO trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas ABCO's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, CON is more volatile compared to ABCO. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check ABCO's competition here
CON vs CYNO Comparison May 2026
CON plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CON stands at 3.3B. In comparison, CYNO has a market cap of 0. Regarding current trading prices, CON is priced at $25.53, while CYNO trades at $66.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CON currently has a P/E ratio of 18.37, whereas CYNO's P/E ratio is N/A. In terms of profitability, CON's ROE is +0.46%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, CON is more volatile compared to CYNO. This indicates potentially higher risk in terms of short-term price fluctuations for CON.Check CYNO's competition here